Clovis down after discontinuing rucaparib bladder cancer trial

Clovis was off $3.08 (13%) to $20.40 in after-hours trading Friday after the company disclosed that it discontinued the Phase II ATLAS trial of Rubraca rucaparib as monotherapy to treat locally advanced unresectable or metastatic urothelial carcinoma.

According to an SEC filing, a preliminary analysis by an IDMC of 62 patients treated with Rubraca showed that the objective response rate (ORR) "does not meet the protocol-defined continuance criteria" and suggests that monotherapy treatment "may not provide a meaningful clinical benefit."...